Table 2.
Type of adjuvant chemotherapy and treatment related adverse effects in women who received adjuvant trastuzumab.
| Interventions/toxicity | N = 39 |
|---|---|
| Received chemotherapy | |
| Docetaxel plus cyclophosphamide | 30 (77) |
| Weekly paclitaxel × 12 | 4 (10) |
| 5FU, epirubicin, and cyclophosphamide followed by docetaxel (FEC-DOC) | 4 (10) |
| Doxorubicin plus cyclophosphamide followed by weekly paclitaxel × 12 | 1 (3) |
| Completed all planned cycles of chemotherapy | 34a (87) |
| Febrile neutropenia | 4 (10) |
| Completed one year of trastuzumab (17 or 18 treatments) | 33 (85) |
| Asymptomatic drop in left ventricle ejection fraction | 10 (26) |
| Symptomatic heart failure | 0 |
a5 patients stopped chemotherapy early due to treatment related side-effects.